Pharming Group NV (PHAR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $891.80M
Last updated: Nov 17, 2026 at 11:03 AM ET
Pharming Group NV (PHAR) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Pharming Group NV reported EPS of $0.30, below the $0.33 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
Analysts' consensus for the quarter ending Dec 31, 2026 is 71.4% below the $0.07 reported for the quarter ended Dec 31, 2025.
PHAR's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
PHAR Earnings Call
The latest PHAR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 29 quarters below that had an estimate, PHAR beat 8, missed 19 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $117.56M, up 20.8% from $97.29M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.30 | $0.33 | $0.02 - $0.39 | -9.09% | Miss | +2900.0% | 2 | 0 up, 0 down | Oct 27, 2026 | $117.56M |
| Jun 30, 2026 | $0.02 | $0.20 | N/A | -90.00% | Miss | +100.0% | 3 | 0 up, 0 down | Jul 30, 2026 | $90.21M |
| Mar 31, 2026 | -$0.07 | $0.01 | -$0.01 - $0.01 | -800.00% | Miss | N/A | 3 | 0 up, 0 down | May 7, 2026 | $72.45M |
| Dec 31, 2025 | $0.07 | $0.01 | $0.01 - $0.02 | +498.29% | Beat | +1300.0% | 2 | 0 up, 1 down | Mar 12, 2026 | $106.50M |
| Sep 30, 2025 | $0.01 | -$0.13 | N/A | +108.00% | Beat | N/A | 2 | 0 up, 0 down | Nov 6, 2025 | $97.29M |
| Jun 30, 2025 | $0.01 | -$0.01 | -$0.03 - $0.00 | +200.00% | Beat | N/A | 2 | 0 up, 0 down | Jul 31, 2025 | $93.22M |
| Mar 31, 2025 | -$0.02 | -$0.02 | -$0.03 - -$0.02 | 0.00% | In line | N/A | 2 | 0 up, 0 down | May 8, 2025 | $79.09M |
| Dec 31, 2024 | $0.01 | $0.01 | $0.01 - $0.01 | -41.18% | Miss | N/A | 2 | 0 up, 1 down | Mar 13, 2025 | $92.70B |
| Sep 30, 2024 | -$0.02 | $0.00 | N/A | -512.00% | Miss | -253.0% | N/A | N/A | Oct 24, 2024 | $74.85M |
| Jun 30, 2024 | -$0.02 | $0.00 | N/A | -785.00% | Miss | -277.0% | N/A | N/A | Aug 1, 2024 | $74.09M |
| Mar 31, 2024 | -$0.02 | $0.01 | N/A | -300.00% | Miss | N/A | N/A | N/A | May 8, 2024 | $55.59M |
| Dec 31, 2023 | -$0.04 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 14, 2024 | $81.87M |
| Sep 30, 2023 | $0.01 | -$0.01 | N/A | +200.00% | Beat | 0.0% | N/A | N/A | Oct 26, 2023 | $66.66M |
| Jun 30, 2023 | $0.01 | -$0.02 | N/A | +150.00% | Beat | 0.0% | N/A | N/A | Aug 3, 2023 | $54.90M |
| Mar 31, 2023 | -$0.02 | -$0.17 | N/A | +88.24% | Beat | -300.0% | N/A | N/A | May 11, 2023 | $42.54M |
| Dec 31, 2022 | -$0.21 | -$0.21 | N/A | +2.38% | Beat | -1466.7% | N/A | N/A | Mar 16, 2023 | $54.62M |
| Sep 30, 2022 | $0.01 | $0.40 | N/A | -97.50% | Miss | N/A | N/A | N/A | Oct 27, 2022 | $54.24M |
| Jun 30, 2022 | $0.01 | $0.01 | N/A | 0.00% | In line | -80.9% | N/A | N/A | Aug 4, 2022 | $50.15M |
| Mar 31, 2022 | $0.01 | $0.05 | N/A | -80.00% | Miss | -93.6% | N/A | N/A | May 12, 2022 | $46.62M |
| Dec 31, 2021 | $0.02 | $0.02 | N/A | -25.00% | Miss | -86.9% | N/A | N/A | Mar 17, 2022 | $45.75M |
| Sep 30, 2021 | $0.00 | $0.04 | N/A | -101.21% | Miss | -103.8% | N/A | N/A | Oct 28, 2021 | $49.44M |
| Jun 30, 2021 | $0.05 | $0.10 | N/A | -47.60% | Miss | +347.9% | N/A | N/A | Aug 9, 2021 | $49.74M |
| Mar 31, 2021 | $0.16 | $0.16 | N/A | -1.88% | Miss | +887.4% | N/A | N/A | Apr 7, 2021 | $43.56M |
| Dec 31, 2020 | $0.11 | $0.11 | N/A | +4.00% | Beat | +845.5% | N/A | N/A | Mar 30, 2021 | N/A |
| Sep 30, 2020 | $0.01 | $0.12 | N/A | -89.00% | Miss | -35.0% | N/A | N/A | Oct 29, 2020 | $58.52M |
| Jun 30, 2020 | $0.01 | $0.15 | N/A | -92.20% | Miss | -32.4% | N/A | N/A | Jul 30, 2020 | $45.27M |
| Mar 31, 2020 | $0.02 | $0.12 | N/A | -86.75% | Miss | +39.5% | N/A | N/A | Jun 29, 2020 | $54.37M |
| Dec 31, 2019 | $0.01 | $0.20 | N/A | -93.95% | Miss | +8.0% | N/A | N/A | Mar 30, 2020 | $54.37M |
| Sep 30, 2019 | $0.02 | $0.18 | N/A | -88.72% | Miss | -22.2% | N/A | N/A | Oct 24, 2019 | $46.35M |
| Jun 30, 2019 | $0.02 | $0.12 | N/A | -85.58% | Miss | +106.0% | N/A | N/A | Jul 26, 2019 | $49.06M |
| Mar 31, 2019 | $0.01 | N/A | N/A | N/A | N/A | +100.0% | N/A | N/A | Jun 29, 2019 | $39.56M |
| Dec 31, 2018 | $0.01 | N/A | N/A | N/A | N/A | +13.1% | N/A | N/A | Mar 30, 2019 | $40.37M |
| Sep 30, 2018 | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2018 | $45.46M |
| Jun 30, 2018 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2018 | $32.39M |
| Mar 31, 2018 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2018 | $36.35M |
| Dec 31, 2017 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2018 | $40.91M |
| Sep 30, 2017 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2017 | $31.55M |
| Jun 30, 2017 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2017 | $18.54M |
| Mar 31, 2017 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2017 | $16.52M |
| Dec 31, 2016 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2017 | $6.94M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.07, a profit after a loss of $0.05 per share the year before. It was -$0.05 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.07 | N/A |
| Dec 31, 2024 | -$0.05 | N/A |
| Dec 31, 2023 | -$0.04 | N/A |
| Dec 31, 2022 | -$0.18 | -178.2% |
| Dec 31, 2021 | $0.22 | +44.3% |
| Dec 31, 2020 | $0.16 | +154.0% |
| Dec 31, 2019 | $0.06 | N/A |
| Dec 31, 2018 | $0.05 | N/A |
| Dec 31, 2017 | -$0.15 | N/A |
| Dec 31, 2016 | -$0.05 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,900 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,918 | 9 | |
| 2026Q2 | Jun 30, 2026 | 6,522 | 11 | |
| 2026Q1 | Mar 31, 2026 | 6,497 | 12 | |
| 2025Q3 | Sep 30, 2025 | 5,069 | 10 | |
| 2025Q2 | Jun 30, 2025 | 5,041 | 8 | |
| 2025Q1 | Mar 31, 2025 | 5,531 | 9 | |
| 2024Q4 | Dec 31, 2024 | 6,034 | 10 | |
| 2024Q3 | Sep 30, 2024 | 2,687 | 8 |
2026Q3 Earnings Call
Opening remarks
Kenneth Lynard Interim Co-CEO Thank you, operator. Good morning and good afternoon, everyone, and thank you for joining Pharming's third-quarter 2026 call. I am joined today by Leverne Marsh, my fellow interim co-CEO and our chief commercial officer, and Dr. Anurag Relan, our chief medical officer. After my opening remarks, Leverne will review our commercial performance, Anurag will cover R&D, and I will return to take you through the financials and outlook before we open the line for questions. As you know, on September 29, Fabrice Chouraqui stepped down as CEO, and the board appointed Leverne and me as interim co-CEOs while it conducts a formal search for a permanent successor. As of now, there are no additional updates to report. Despite these changes, our strategy, pipeline, and commitment to patients remain unchanged. Before we begin, please note that we will be making forward-looking statements on this call. These are based on our current expectations and plans, and actual results may differ materially. Please refer to the full statement on this slide. We are pleased to report a strong third-quarter performance. Before I go further, I want to comment on why we decided to report results today rather than on November 5, as originally scheduled. Because our third-quarter results came in above analyst consensus, we issued a pre-release on October 22 with top-line revenues and operating expenses only. We appreciated that, once these numbers were public, investors would want to see the full details behind them as soon as possible and have the opportunity to ask questions. As a result, we moved up the date for our full third-quarter disclosure to today. The change in date is not related to any transaction or restructuring of the company. Getting back to this slide, as many of you who have followed Pharming know, our strategy rests on three pillars. RUCONEST continues to provide a durable source of cash flow, and I am pleased to report it has returned to growth this quarter. Joenja, a high-growth asset still early in its life cycle, is expanding geographically and with a new pediatric indication. And we have a high-value clinical pipeline with two potential billion-dollar opportunities: leniolisib in broader primary immunodeficiencies, including CVID, and nepasimone in mitochondrial DNA-driven primary mitochondrial disease. Turning to the quarter in more detail, total revenue grew 21% to $117.6 million, ahead of market expectations. This quarter, RUCONEST returned to revenue growth, Joenja sales grew 58%, and our operating profit increased by 89%. We are also tightening our full-year revenue guidance to $380 million to $390 million and lowering our operating expense guidance to $310 million to $315 million. Both of our commercial products contributed to growth.
Frequently Asked Questions About PHAR
Did PHAR beat earnings estimates last quarter?
No. Pharming Group NV reported EPS of $0.30 for the quarter ended Sep 30, 2026, below the $0.33 estimate by 9.09%.
What EPS do analysts expect from PHAR next quarter?
The consensus EPS estimate for Pharming Group NV for the quarter ending Dec 31, 2026 is $0.02 from 5 analysts, with estimates from $0.02 to $0.03.
How often does PHAR beat earnings estimates?
Pharming Group NV beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -16.75%.
PHAR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors